Novartis Q4 Results
↓
↑
INNOVATION
Content
Click below to navigate
through the document
We have signed >15 strategic deals during the last year, totaling >6bn USD, to
enhance our pipeline across core therapeutic areas and technology platforms
Company overview
Financial review
Select recent examples
Conclusions
Appendix
信瑞诺
SanReno
Calypso
CHINOOK
biotech
THERAPEUTICS
THERAPEUTICS
References
IONIS XRNA
Argo
Biopharma
XRNA
Chong Kun Dang
Pharm.
Seoul, Korea
CRM
CLOVIS ONCOLOGY RLT
voyager
Gene
therapy
Bicycle RLT
therapeutics
AVROBIO Gene
DTX XRNA
PHARMA
therapy
Note: Number of strategic M&A and BD&L transactions announced, value reflecting upfront payments.
□ NOVARTIS | Reimagining Medicine.
LEGEND Cell
BIOTECH
therapy
14 Isomorphic Labs
Immunology
Neuroscience
Oncology
Novartis Q4 Results | January 31, 2024
21View entire presentation